27:
308:(RRP). These trials were initiated prior to the discovery that potency could be greatly enhanced by addition of a vaccine adjuvant. Nventa is currently developing HspE7 combined with the TH1-directed adjuvant Poly-ICLC. A Phase 1b study is complete, assessing safety and tolerability in 17 patients with CIN.
331:
The transaction will be effected by an exchange of Akela common shares for the outstanding shares of Nventa on the basis of 0.0355 Akela shares for each Nventa share, resulting in about 70/30 ownership split between Akela and Nventa shareholders, respectively, in the combined entity.
341:
On May 22, 2009, Akela and Nventa announced the closing of the arrangement agreement to combine the two companies and that the transaction has been approved by the shareholders of Nventa, the
British Columbia Supreme Court and the Toronto Stock Exchange.
327:
On March 27, 2008, Akela Pharma Inc. and Nventa
Biopharmaceuticals Corporation announced the execution of an arrangement agreement to combine the two companies by way of a plan of arrangement under the Business Corporations Act.
449:
Neefe, JR; Smith, RJ; McClay, J; Van Burik, JA; Wiatrak, BJ; Arnold, J; Berger, B; Neefe, JR (2005). "HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial".
600:
605:
620:
429:
615:
335:
The public company will retain Akela's name, will operate under Akela's management, and will continue to be listed on the
Toronto Stock Exchange under the ticker symbol AKL.
630:
610:
250:
According to the annual information form, for the year ending
December 31, 2009, provided on Akela Pharma's website, scientific research funding has ceased for HspE7.
304:
Nventa originally advanced HspE7 as a single-agent therapy into multiple Phase 2 clinical trials with positive results, including trials in cervical dysplasia and
635:
296:
of tumors and preventing tumor growth in mouse models. The company developed Poly-ICR for both internal use and for external licensing opportunities.
496:
512:
625:
513:"ClinicalTrialsFeeds.org, Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia"
558:
547:
232:
288:) immune responses against that antigen. As yet unpublished pre-clinical data indicate that Poly-ICR, in combination with a
201:
intended for the treatment of HPV-related diseases. HspE7 is derived from Nventa’s patented CoVal fusion platform that uses
430:"Drugs.com, Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia"
392:
417:
178:
253:
Nventa is also developing two additional therapeutic vaccine programs based on its CoVal technology—a Hsp – HBV (
177:(Hsp) technology to target the over 20 million Americans already infected with HPV. Previously headquartered in
305:
272:
vaccines. Poly-ICR is a TLR3 agonist that, when combined with a disease-specific antigen, can induce both
51:
570:
217:
responses to specific diseases. Nventa is developing HspE7 in combination with the Toll-like receptor 3 (
493:
338:
Nventa noted that it would have the right to nominate two directors to the board of directors of Akela.
293:
158:
115:
105:
516:
358:
265:
225:
214:
170:
492:
International HPV Conference Poster: “NVENTA PRESENTS HSPE7 DATA AT INTERNATIONAL HPV CONFERENCE” /
583:
26:
536:
475:
236:
174:
467:
459:
500:
244:
202:
37:
594:
289:
206:
62:
45:
479:
273:
240:
269:
254:
463:
378:
258:
228:
471:
396:
281:
416:
Company Press
Release, “NVENTA DEVELOPS PROPRIETARY VACCINE ADJUVANT” /
268:, Poly IC – Poly Arginine (Poly-ICR), for use with both therapeutic and
264:
In June 2008, Nventa announced the development of a proprietary vaccine
222:
210:
198:
157:
was a
Canadian-incorporated biopharmaceutical company headquartered in
584:
Company Press
Release, "Akela and Nventa Announce Closing of Merger" /
285:
277:
166:
95:
292:, increases antigen-specific CD8 T-cell levels, while both inducing
218:
194:
162:
319:
Peter Emtage, Ph.D., Vice
President, Research and Development
182:
393:"Fierce Biotech, Nventa Consolidates Offices Into San Diego"
146:
359:"Could Our Own Proteins Be Used to Help Us Fight Cancer?"
316:
Gregory M. McKee, President and Chief
Executive Officer
173:(HPV). Nventa is currently the only company applying
257:) fusion, and prototypes of Hsp fusion proteins with
601:
Defunct biotechnology companies of the United States
571:"Latest Canadian News, Headlines and Breaking News"
181:, Canada, the company’s common stock traded on the
142:
132:
122:
111:
101:
91:
76:
68:
58:
43:
33:
606:Defunct technology companies based in California
621:Biotechnology companies disestablished in 2009
161:developing therapeutics for the treatment of
8:
19:
616:Biotechnology companies established in 1990
18:
631:1990 establishments in British Columbia
611:Technology companies based in San Diego
379:"Genital HPV Infection: CDC Fact Sheet"
350:
494:Nventa Press Release, November 5, 2007
155:Nventa Biopharmaceuticals Corporation
7:
636:2009 disestablishments in California
306:recurrent respiratory papillomatosis
231:for multiple indications, including
209:fuse heat shock proteins to target
72:1990 (as Stressgen Biotechnologies)
233:Cervical Intraepithelial Neoplasia
14:
559:Business Week: Executive Profile
548:Business Week: Executive Profile
169:, focusing on diseases caused by
25:
323:Merger with Akela Pharma, Inc.
193:The company’s lead candidate,
1:
626:2009 mergers and acquisitions
247:, and head and neck cancers.
537:Nature Biotechnology: People
16:Canadian healthcare company
652:
499:November 21, 2008, at the
464:10.1177/000348940511400913
179:Victoria, British Columbia
197:, is a novel therapeutic
24:
20:Nventa Biopharmaceuticals
452:Ann Otol Rhinol Laryngol
290:tumor-associated antigen
185:under the symbol: NVN.
215:cellular immune system
213:, thereby stimulating
183:Toronto Stock Exchange
159:San Diego, California
116:San Diego, California
189:Development programs
171:human papillomavirus
134:Number of employees
21:
381:. 19 January 2021.
237:cervical dysplasia
175:heat shock protein
147:www.nventacorp.com
312:Senior management
300:Clinical progress
152:
151:
106:Akela Pharma, Inc
643:
586:
581:
575:
574:
567:
561:
556:
550:
545:
539:
534:
528:
527:
525:
524:
515:. Archived from
509:
503:
490:
484:
483:
446:
440:
439:
437:
436:
426:
420:
414:
408:
407:
405:
404:
395:. Archived from
389:
383:
382:
375:
369:
368:
366:
365:
355:
163:viral infections
128:Gregory M. McKee
87:
85:
29:
22:
651:
650:
646:
645:
644:
642:
641:
640:
591:
590:
589:
582:
578:
569:
568:
564:
557:
553:
546:
542:
535:
531:
522:
520:
511:
510:
506:
501:Wayback Machine
491:
487:
448:
447:
443:
434:
432:
428:
427:
423:
415:
411:
402:
400:
391:
390:
386:
377:
376:
372:
363:
361:
357:
356:
352:
348:
325:
314:
302:
245:cervical cancer
235:(also known as
203:recombinant DNA
191:
135:
125:
118:, United States
83:
81:
48:
17:
12:
11:
5:
649:
647:
639:
638:
633:
628:
623:
618:
613:
608:
603:
593:
592:
588:
587:
576:
562:
551:
540:
529:
504:
485:
441:
421:
409:
384:
370:
349:
347:
344:
324:
321:
313:
310:
301:
298:
205:technology to
190:
187:
150:
149:
144:
140:
139:
136:
133:
130:
129:
126:
123:
120:
119:
113:
109:
108:
103:
99:
98:
93:
89:
88:
78:
74:
73:
70:
66:
65:
60:
56:
55:
49:
44:
41:
40:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
648:
637:
634:
632:
629:
627:
624:
622:
619:
617:
614:
612:
609:
607:
604:
602:
599:
598:
596:
585:
580:
577:
572:
566:
563:
560:
555:
552:
549:
544:
541:
538:
533:
530:
519:on 2011-07-25
518:
514:
508:
505:
502:
498:
495:
489:
486:
481:
477:
473:
469:
465:
461:
457:
453:
445:
442:
431:
425:
422:
419:
418:June 18, 2008
413:
410:
399:on 2011-07-11
398:
394:
388:
385:
380:
374:
371:
360:
354:
351:
345:
343:
339:
336:
333:
329:
322:
320:
317:
311:
309:
307:
299:
297:
295:
291:
287:
283:
279:
275:
271:
267:
262:
260:
256:
251:
248:
246:
242:
241:genital warts
238:
234:
230:
227:
224:
220:
216:
212:
208:
204:
200:
196:
188:
186:
184:
180:
176:
172:
168:
164:
160:
156:
148:
145:
141:
137:
131:
127:
121:
117:
114:
110:
107:
104:
100:
97:
94:
90:
79:
75:
71:
67:
64:
63:Biotechnology
61:
57:
53:
50:
47:
42:
39:
36:
32:
28:
23:
579:
565:
554:
543:
532:
521:. Retrieved
517:the original
507:
488:
458:(9): 730–7.
455:
451:
444:
433:. Retrieved
424:
412:
401:. Retrieved
397:the original
387:
373:
362:. Retrieved
353:
340:
337:
334:
330:
326:
318:
315:
303:
270:prophylactic
263:
252:
249:
192:
154:
153:
112:Headquarters
34:Company type
255:hepatitis B
595:Categories
523:2008-05-05
435:2007-03-05
403:2007-05-31
364:2008-07-01
346:References
294:regression
261:antigens.
207:covalently
124:Key people
54:: NVN
274:cytotoxic
259:influenza
239:or CIN),
229:Poly-ICLC
102:Successor
46:Traded as
497:Archived
480:42379118
472:16240938
282:antibody
266:adjuvant
226:adjuvant
211:antigens
59:Industry
223:agonist
199:vaccine
143:Website
82: (
77:Defunct
69:Founded
478:
470:
286:B cell
280:) and
278:T cell
167:cancer
96:Merged
38:Public
476:S2CID
195:HspE7
468:PMID
219:TLR3
165:and
92:Fate
84:2009
80:2009
460:doi
456:114
52:TSX
597::
474:.
466:.
454:.
243:,
221:)
573:.
526:.
482:.
462::
438:.
406:.
367:.
284:(
276:(
138:5
86:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
